Press Releases

Title Company Date
Insmed renegotiates Term Loan with Pharmakon Resulting in a Lower Cost of Capital and an Additional $150 Million in Proceeds to be Received in the Fourth Quarter Insmed October 2024
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors Geron October 2024
ATEC Spine, Inc. Reports Third Quarter 2024 Financial Results And Raises Full-Year Guidance Alphatec October 2024
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology Collegium July 2024
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon – Novocure Novocure May 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon Tarsus April 2024
Pharmakon Advisors provides $275 Million Debt Facility to Reata Pharmaceuticals Reata May 2023
BioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon BioCryst April 2023
ImmunoGen signs loan agreement with Pharmakon for up to $125m ImmunoGen April 2023
Immunocore Loan Immunocore November 2022
Insmed Announces Strategic Financings Totalling $775 Million Insmed October 2022
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven UroGen March 2022
Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio Collegium February 2022
Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Coherus January 2022
Evolus Enters Into $125 Million Credit Facility with Pharmakon Advisors Evolus December 2021
Collegium Announces Closing of the Nucynta Franchise Acquisition Collegium February 2020
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing Sarepta December 2019
AKEBIA SECURES $100 MILLION NON-DILUTIVE TERM LOAN FINANCING; REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Akebia NOVEMBER 2019
Optinose Announces $150 Million Debt Financing from Pharmakon Optinose September 2019
Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders Amicus September 2018
Novocure Secures New $150 Million Non-Dilutive Term Loan Financing Novocure February 2018
Depomed Announces Prepayment of $100 Million of Secured Debt Facility Depomed April 2017
BioPharma Credit PLC US$ 762 million IPO and admission to trading on the London Stock Exchange, bringing total capital raised by Pharmakon funds to US$ 2.4 billion BioPharma Credit PLC April 2017
Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors Novocure January 2015
Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition Depomed March 2015
Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors Novocure January 2015
Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facility Corcept August 2012

Disclaimer

Copyright © 2024 Pharmakon Advisors, LP, All Rights Reserved.
Website Design By Alex Delmont Limited

 

The content of this website is provided by Pharmakon Advisors, LP (“Pharmakon”) and offers information about Pharmakon and its affiliates and a general overview of its investment program. The content of this website is provided for information purposes only. Nothing on this website shall be construed as an offer to sell or a solicitation of an offer to purchase interests in any fund, private, publicly listed or otherwise, managed by Pharmakon, nor do they constitute investment advice. The information contained herein is subject to change without notice.

Please click on a transaction in order to view the corresponding press release.  Nothing in any applicable press release is intended to be, nor should be construed as, a testimonial or endorsement regarding Pharmakon as an investment adviser.  No compensation has been provided to any executives providing statements regarding Pharmakon, but, due to Pharmakon’s client’s investment in the relevant issuers, any statements made regarding Pharmakon in the press release involve an inherent conflict of interest.  To Pharmakon’s knowledge, none of the officers or directors of the borrowers quoted in any applicable press release are clients or investors in funds managed by Pharmakon.

Offers and sales will be made only in accordance with applicable securities laws and pursuant to a confidential private placement memorandum (or similar document) and other applicable fund governing documents, which should be read carefully and in their entirety prior to making an investment. Potential investors should not rely on any of the content of this website in making an investment or other decision but should obtain relevant and specific professional advice.

The content of this website and the investment program or the shares of any company which might be referred to therein are not directed at, or intended for, distribution, directly or indirectly, to any person or entity being a citizen or resident of, or located or established in, any jurisdiction where (i) the use of such websites or the sale of such investment programs would be illegal or would require any registration or licensing not held by Pharmakon, or (ii) to do so would constitute a violation of applicable law or regulation. Such persons or entities access this website at their own risk and must observe any legal or regulatory restrictions which may affect their eligibility to access this website.  Pharmakon makes no warranty or guarantee as to the accuracy, completeness or reliability of any information contained on this website. Pharmakon shall have no liability for any direct, indirect, consequential or special losses or damages of any kind whatsoever arising from reliance on any of the content of this website.

This website is for general information purposes only and is subject to change without notice. Nothing on this website is intended to and does not constitute financial, accounting, tax, legal, investment, consulting or other professional advice or services.

I decline I understand and agree
Loading...